Hikma Pharmaceuticals Company Insiders
| HKMPY Stock | USD 49.81 0.70 1.39% |
Hikma Pharmaceuticals employs about 8.7 K people. The company is managed by 10 executives with a total tenure of roughly 56 years, averaging almost 5.0 years of service per executive, having 870.0 employees per reported executive. Break down of Hikma Pharmaceuticals' management performance can provide insight into the company performance.
| Mazen Darwazah Chairman Executive Vice Chairman, Member of Compliance, Responsibility and Ethics Committee, Member of Nomination Committee, CEO of MENA and Emerging Markets and President of MENA and Emerging Markets |
| Riad Mishlawi President EU Vice President and Global Head - Injectables |
Hikma |
Hikma Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of 0.077 % which means that it generated a profit of $0.077 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.154 %, meaning that it generated $0.154 on every $100 dollars invested by stockholders. Hikma Pharmaceuticals' management efficiency ratios could be used to measure how well Hikma Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Hikma Pharmaceuticals Workforce Comparison
Hikma Pharmaceuticals PLC is one of the top stocks in number of employees category among its peers. The total workforce of Drug Manufacturers—Specialty & Generic industry is currently estimated at about 83,293. Hikma Pharmaceuticals retains roughly 8,700 in number of employees claiming about 10% of equities under Drug Manufacturers—Specialty & Generic industry.
The company has Profit Margin (PM) of 0.14 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.22 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.22. Hikma Pharmaceuticals PLC Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Hikma Pharmaceuticals PLC Price Series Summation is a cross summation of Hikma Pharmaceuticals price series and its benchmark/peer.
Hikma Pharmaceuticals Notable Stakeholders
A Hikma Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Hikma Pharmaceuticals often face trade-offs trying to please all of them. Hikma Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Hikma Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Mazen Darwazah | Executive Vice Chairman, Member of Compliance, Responsibility and Ethics Committee, Member of Nomination Committee, CEO of MENA and Emerging Markets and President of MENA and Emerging Markets | Profile | |
| Riad Mishlawi | EU Vice President and Global Head - Injectables | Profile | |
| Susan Ringdal | Vice President - Corporate Strategy and Investor Relations | Profile | |
| Majda Labadi | Corporate Vice President - Human Resources | Profile | |
| Engineer Darwazah | Ex CEO | Profile | |
| Khalid Nabilsi | Chief Officer | Profile | |
| CPA CFA | Exec MA | Profile | |
| Brian Hoffmann | Pres Generics | Profile | |
| Hussein Arkhagha | General Counsel | Profile | |
| Samuel Park | Global US | Profile |
About Hikma Pharmaceuticals Management Performance
The success or failure of an entity such as Hikma Pharmaceuticals PLC often depends on how effective the management is. Hikma Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Hikma management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Hikma management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company was founded in 1978 and is based in London, the United Kingdom. Hikma Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 8700 people.
Please note, the imprecision that can be found in Hikma Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Hikma Pharmaceuticals PLC. Check Hikma Pharmaceuticals' Beneish M Score to see the likelihood of Hikma Pharmaceuticals' management manipulating its earnings.
Hikma Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Hikma Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Hikma Pharmaceuticals within its industry.Hikma Pharmaceuticals Manpower Efficiency
Return on Hikma Pharmaceuticals Manpower
| Revenue Per Employee | 293.4K | |
| Revenue Per Executive | 255.3M | |
| Net Income Per Employee | 48.4K | |
| Net Income Per Executive | 42.1M | |
| Working Capital Per Employee | 80.6K | |
| Working Capital Per Executive | 70.1M |
Additional Tools for Hikma Pink Sheet Analysis
When running Hikma Pharmaceuticals' price analysis, check to measure Hikma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hikma Pharmaceuticals is operating at the current time. Most of Hikma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Hikma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hikma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Hikma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.